Insider Selling: uniQure (NASDAQ:QURE) Director Sells 2,645 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 2,645 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $30.01, for a total transaction of $79,376.45. Following the transaction, the director directly owned 20,439 shares in the company, valued at $613,374.39. This trade represents a 11.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Down 5.5%

NASDAQ QURE traded down $1.54 during trading hours on Friday, hitting $26.45. The company’s stock had a trading volume of 1,448,107 shares, compared to its average volume of 2,673,993. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The company has a market capitalization of $1.67 billion, a PE ratio of -7.60 and a beta of 0.98. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The company’s 50-day simple moving average is $21.19 and its two-hundred day simple moving average is $21.83.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. Research analysts anticipate that uniQure N.V. will post -3.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on QURE shares. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and raised their price target for the company from $12.00 to $35.00 in a research report on Wednesday, March 11th. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and raised their price target for the company from $11.00 to $35.00 in a research report on Monday, March 9th. Wolfe Research initiated coverage on shares of uniQure in a research report on Monday, February 23rd. They set a “peer perform” rating on the stock. Finally, The Goldman Sachs Group lifted their target price on shares of uniQure from $9.00 to $10.00 and gave the stock a “neutral” rating in a research report on Monday, April 20th. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.83.

Hedge Funds Weigh In On uniQure

Several hedge funds have recently modified their holdings of QURE. Torren Management LLC bought a new position in shares of uniQure during the 4th quarter worth approximately $28,000. Jones Financial Companies Lllp lifted its position in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares in the last quarter. IFP Advisors Inc bought a new position in shares of uniQure during the 4th quarter worth approximately $48,000. Smartleaf Asset Management LLC bought a new position in shares of uniQure during the 4th quarter worth approximately $48,000. Finally, CIBC Private Wealth Group LLC bought a new position in shares of uniQure during the 3rd quarter worth approximately $50,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.